Effects of ciprofloxacin and ofloxacin on adult human cartilage in vitro

Menschik, M.; Neumüller, Josef; Steiner, Carl-Walter; Erlacher, L; Köller, Marcus; Ullrich, Robert C.; Graninger, W

doi:10.1128/aac.41.11.2562

Cited by 35 publications

(20 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Various molecular mechanisms have been postulated for arthropathy, such as inhibition of synthesis of collagen and glycosaminoglycans, inhibition in mitochondrial function resulting in generation of free radicals and oxidative stress or chelation of magnesium ions, all culminating in cartilage and tendon damage 5 123…”

Section: Discussionmentioning

confidence: 99%

Ciprofloxacin safety in paediatrics: a systematic review

Adefurin

Sammons

Jacqz-Aigrain

et al. 2011

Archives of Disease in Childhood

145

View full text Add to dashboard Cite

ObjectiveTo determine the safety of ciprofloxacin in paediatric patients in relation to arthropathy, any other adverse events (AEs) and drug interactions.MethodsA systematic search of MEDLINE, EMBASE, CINAHL, CENTRAL and bibliographies of relevant articles was carried out for all published articles, regardless of design, that involved the use of ciprofloxacin in any paediatric age group ≤17 years. Only articles that reported on safety were included.Results105 articles met the inclusion criteria and involved 16 184 paediatric patients. There were 1065 reported AEs (risk 7%, 95% CI 3.2% to 14.0%). The most frequent AEs were musculoskeletal AEs, abnormal liver function tests, nausea, changes in white blood cell counts and vomiting. There were six drug interactions (with aminophylline (4) and methotrexate (2)). The only drug related death occurred in a neonate who had an anaphylactic reaction. 258 musculoskeletal events occurred in 232 paediatric patients (risk 1.6%, 95% CI 0.9% to 2.6%). Arthralgia accounted for 50% of these. The age of occurrence of arthropathy ranged from 7 months to 17 years (median 10 years). All cases of arthropathy resolved or improved with management. One prospective controlled study estimated the risk of arthropathy as 9.3 (OR 95% CI 1.2 to 195). Pooled safety data of controlled trials in this review estimated the risk of arthropathy as 1.57 (OR 95% CI 1.26 to 1.97).ConclusionMusculoskeletal AEs occur due to ciprofloxacin use. However, these musculoskeletal events are reversible with management. It is recommended that further prospective controlled studies should be carried out to evaluate the safety of ciprofloxacin, with particular focus on the risk of arthropathy.

show abstract

Section: Discussionmentioning

confidence: 99%

Ciprofloxacin safety in paediatrics: a systematic review

Adefurin

Sammons

Jacqz-Aigrain

et al. 2011

Archives of Disease in Childhood

145

View full text Add to dashboard Cite

show abstract

“…1,2 It acts mainly by inhibiting a type II topoisomerase, DNA gyrase, which is necessary for the unwinding of replicated prokaryotic DNA. 2 It has been shown, however, that this mechanism can also affect mammalian cell replication through the inhibition of eukaryotic topoisomerases.…”

Section: Introductionmentioning

confidence: 99%

Role of Mitochondria in Ciprofloxacin-Induced Apoptosis in Murine Sperm Cells

et al. 2013

View full text Add to dashboard Cite

show abstract

“…These chronic and intermittent loads to the joint cartilage induce production of nitrogen oxide (NO) and nitrogen oxide synthase which damage the joint cartilage (Fermor et al, 2001). The frequent intake of antibiotics, especially the gyrase inhibitor, may further reduce the strength of the temporomandibular joint and surrounding structure (Menschik et al, 1997).…”

Section: Discussionmentioning

confidence: 99%